<unk> , sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.<unk>  was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
Ranibizumab
Ruxolitinib
Abrocitinib
Gilteritinib
Erdafitinib
Sorafenib
Avelumab
Nintedanib